Navigation Links
Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
Date:7/14/2009

TAMPA, Fla., July 14 /PRNewswire/ -- Quantum Immunologics, Inc. (QI), a Tampa, Florida company focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast cancer trial has begun to receive its dendritic cell therapy.

QI is currently sponsoring and conducting an FDA-authorized Phase I/II clinical trial testing the safety and efficacy of its immunotherapy on 27 Stage IV breast cancer patients who have failed conventional therapy. According to Mr. Chuck Broes, CEO of QI, "This achievement marks a significant milestone in the life cycle of our company, and we look forward with great hope and commitment as we aspire to a successful trial outcome."

The clinical trials involve the use of dendritic cell therapy using the oncofetal antigen ("OFA"), or iLRP -- immature Laminin Receptor Protein, as a cancer antigen (a protein found on cancer cells that can be targeted by the body's own immune system) found in many tumor cell lines or fetal tissue, but absent on normal, healthy tissue. QI believes that the OFA antigen can serve as a unique, valuable and promising antigen for individualized breast cancer immunotherapy.

Centered in Mobile, AL, QI's clinical trial is designed around the use of QI's proprietary dendritic cell therapy, which employs OFA to recruit the patient's own immune system to target and attack the cancer cells with the intent to improve patient survivability and quality of life. Each patient will receive three monthly injections of the patient's own dendritic cells that have been sensitized to OFA. It is anticipated that once the sensitized cells are injected back into the patient, the patient's T-cells will locate the OFA found on the patient's cancer cells, thereby generating an immune response with the goal of killing the cancer cells and preventing further spread of the disease.

Abo
'/>"/>

SOURCE Quantum Immunologics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
2. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
3. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
6. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
7. Immunotherapy-Based Provisional Patents Mark Significant Discovery
8. Cord Blood America Sees Significant Positives in President Obamas Lifting of Stem Cell Funding Restrictions
9. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
10. Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
11. iCardiac Reports Significant Revenue Growth and Profitability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 GliaCure, a privately-held ... therapies for neurological and neuropsychiatric disorders based on ... of Alzheimer,s patients in a Phase 1b clinical ... compound developed as a potential disease-modifying treatment. GliaCure,s ... in that it both promotes the clearance of ...
(Date:5/4/2015)... TEL AVIV, Israel , May 4, 2015 /PRNewswire/ ... has filed its annual report on Form 20-F for ... U.S. Securities and Exchange Commission ("SEC"). The annual report ... for the development of antibodies in the area of ... antibodies with superior qualities of high specificity and binding ...
(Date:5/4/2015)... , May 4, 2015  Traverse Biosciences ... cooperative research and development agreement (CRADA) with Aratana ... the development of TRB-N0224 for the treatment and ... dogs and cats.  Traverse Biosciences has also granted ... the treatment and control of periodontal disease in ...
(Date:5/4/2015)... - Fluorinov Pharma (Fluorinov), a FACIT portfolio company, ... Roger J Garceau, to its Board of Directors. ... including corporate development and clinical strategy, his appointment ... expertise as Fluorinov transitions to clinical development.  ... pharmaceutical development experience to Fluorinov and most recently ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3
... January 12 New Delhi based Mayuka Labs,Private Limited ... from the department of scientific and industrial,research (DSIR) under ... With twenty-one scientists working round ... Mayuka Labs has crossed this milestone in its first ...
... HUBBARD, Ohio, Jan. 12 NanoLogix, Inc. (OTC: NNLX) ... update. NanoLogix welcomes Daniel Barnhizer and Jeff Long to ... professor of law at Michigan State University ... the areas of business, contract, securities, and commercial law. ...
... The French agency Agence de Medecine,Preventive (AMP) ... as,Program Director for the SIVAC (Supporting Independent Immunization ... contributing to,the development of national immunization technical advisory ... six in Asia. These committees will help,national health ...
Cached Biology Technology:Mayuka Labs R&D Centre Gets DSIR Recognition 2NanoLogix Inc. Appoints Two New Directors and Provides Operations Update 2NanoLogix Inc. Appoints Two New Directors and Provides Operations Update 3French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 2French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 3
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... time, breast cancers from Nigeria, Senegal and North America ... likely to be diagnosed with a more virulent form ... Researchers from the University of Chicago, working with colleagues ... University of North Carolina, found that breast cancers in ...
... certain parts of the brain, cells called neurons go ... from Rockefeller University's Fernando Nottebohm, Ph.D., shows that these ... that die in people with diseases such as Alzheimer's ... protein called UCHL1. , "It would be ironic if ...
... testing the safety of an experimental vaccine targeting West ... of Health's (NIH) Clinical Center in Bethesda, MD. The ... adult volunteers, was developed for human clinical studies by ... Diseases' (NIAID) Vaccine Research Center (VRC), and Vical Inc., ...
Cached Biology News:Study reveals dramatic difference between breast cancers in US and Africa 2Study reveals dramatic difference between breast cancers in US and Africa 3Study reveals dramatic difference between breast cancers in US and Africa 4One gene links newborn neurons with those that die in diseases such as Alzheimer's 2One gene links newborn neurons with those that die in diseases such as Alzheimer's 3One gene links newborn neurons with those that die in diseases such as Alzheimer's 4NIAID begins clinical trial of West Nile virus vaccine 2NIAID begins clinical trial of West Nile virus vaccine 3
... The membrane filters suitable for use in the ... top of each filter, in a specially designed ... special pleating of the band of membrane filter ... dispensed. The shape of the sealed band guarantees ...
... PRKAR2 cAMP is a signaling molecule ... cAMP exerts its effects by activating the ... signal through phosphorylation of different target proteins. ... tetramer composed of two regulatory and two ...
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
...
Biology Products: